Revolutionizing treatment for patients in need
Scroll To Discover
About
We’re committed to delivering boundless therapeutic ingenuity
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of conditions with limited treatment options.
Pipeline
Novel therapies, beginning with the eye
For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.
News & Media
Here is the latest from Tarsus
03/31/2021
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
03/29/2021
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
01/19/2021
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
2021 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below.